Staging for endometrial carcinoma FIGO 2023 and its relevance for clinical practice.
| Autor: | Sehnal B, Kubecová M, Hruda M, Drozenová J, Halaška JM, Havlík J, Robová H, Pichlík T, Grafnetter Regináčová K, Rob L |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti [Klin Onkol] 2024; Vol. 38 (4), pp. 250-258. |
| DOI: | 10.48095/ccko2024250 |
| Abstrakt: | Background: International Federation of Gynaecology and Obstetrics (Fédération Internationale de Gynécologie et d'Obstétrique - FIGO) introduced a new staging system for endometrial carcinoma - FIGO 2023 - in June 2023. Objective: The new staging system differs significantly from previous versions. The new system represents a significant departure from the traditional staging systems for other gynaecological cancers, as the definition of individual stages includes not only the traditional anatomical extent of the tumour, but also the molecular profile of the tumour and other histopathological parameters - histological type of tumour, tumour grade and the presence of substantial lymphovascular invasion. The new system defines stages I and II in a completely different way and expands the definition of stages III and IV, allowing for different types of tumour spread outside the uterus. The introduction of molecular testing is the main change in the new staging system. When certain molecular markers are detected, stage I or II is completely changed. By including these non-anatomical parameters, the FIGO 2023 staging system improves the accuracy of a patient's prognosis at a specific stage with better options for individualized treatment, including the use of immunotherapy. Another goal was to synchronise staging as much as possible with the recommendations of three professional societies: the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP). The staging system for carcinosarcoma remains identical to the staging system for endometrial cancer. Conclusion: This article presents an overview of the new FIGO 2023 endometrial cancer staging system and discusses its advantages and disadvantages for clinical practice. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|